Small Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd.

JAGSNPHARM

₹231.03

0.64% (1.47)

Market Cap

₹1,526 Cr.

P/E

27.57

Jagsonpal Pharmaceuticals Ltd.
Overview
Financials
Benchmarking
Shareholding

Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd.
Overview
Financials
Benchmarking
Shareholding

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Jagsonpal Pharmaceuticals Ltd. Shareprice

Has the share price of Jagsonpal Pharma grown faster than its competition?

Jagsonpal Pharma has given better returns compared to its competitors.
Jagsonpal Pharma has grown at ~56.73% over the last 7yrs while peers have grown at a median rate of 40.84%

Is Jagsonpal Pharma stock expensive?

Jagsonpal Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Jagsonpal Pharma is 27.57, while 3 year average PE is 37.38.
Also latest EV/EBITDA of Jagsonpal Pharma is 27.36 while 3yr average is 27.15.

View FAQ's On Business

Growth Table

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	69.48	24.80	21.11	39.52	69.84	68.05	57.29	41.22	34.01	35.99
TTM EPS CAGR	147	44.80	42.72	33.96	33.79	37.07	—	21.28	36.94	50.35
Sales CAGR	28.76	6.55	7.29	9.35	7.62	8.27	11.35	8.03	7.17	6.88
PAT Margin (Abs Growth)	-0.38	2.24	0.94	5.05	5.69	19.14	1.83	7.75	9.17	8.55
PE CAGR	-31.01	-14.25	-14.02	4.03	26.83	22.35	—	16.53	-2.51	-8.99
CFO CAGR	-24.63	126	7.61	31.15	2.62	—	—	18.51	26.31	16.68

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	159	143	130	136	149	164	171	203	226	278
Non Current Assets	54.71	29.24	32.02	35.11	49.30	41.87	51.91	28.22	15.75	117
Net Block	51.61	21.59	21.32	21.64	24.44	25.72	22.60	24.28	9.30	86.23
Capital Work in Progress	0.00	0.00	3.04	3.95	1.90	0.00	0.00	0.00	0.00	—
Intangible Assets Under Development	—	—	2.06	2.06	2.35	—	—	—	—	—
Long Term Investments	0.00	0.00	0.00	0.00	11.39	12.06	28.86	1.12	—	—
Current Assets	101	110	94.61	97.56	96.31	120	116	172	191	161
Inventory	39.84	47.62	51.43	32.69	29.32	29.72	29.74	20.68	15.00	15.20
Accounts Receivable	41.69	39.41	25.15	20.75	21.45	12.66	15.58	20.87	10.95	13.18
Short Term Investments	—	—	—	—	—	3.25	21.81	—	—	—
Cash & Bank Balances	15.53	20.06	14.51	38.53	40.49	60.23	25.25	115	148	129
Liabilities	159	143	130	136	149	164	171	203	226	278
Shareholders Funds	98.36	110	98.05	104	111	122	133	159	187	240
Share Capital	13.10	13.10	13.10	13.10	13.10	13.10	13.10	13.10	13.22	13.28
Reserves	85.27	96.81	84.95	91.37	97.93	109	120	137	157	227
Non Current Liabilities	3.61	3.26	3.19	3.12	3.09	1.88	4.49	8.48	10.55	12.41
Secured Loans	—	—	—	—	—	—	—	—	—	—
Unsecured Loans	—	—	—	—	—	—	—	—	—	—
Current Liabilities	57.31	29.44	28.58	28.19	34.57	40.40	34.14	35.18	27.64	25.90
Accounts Payable	9.73	8.98	9.09	11.86	11.71	18.05	18.55	16.58	7.60	9.73
Short Term Loans	38.49	7.93	8.30	3.79	6.40	6.79	—	—	—	—

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	143	144	127	167	159	188	218	237	209	269
Operating Expenses	132	138	138	157	150	169	193	203	186	218
Raw Material	56.28	53.87	26.89	38.79	36.78	77.27	31.91	31.21	22.10	18.34
Others	56.28	53.87	26.89	38.79	36.78	77.27	31.91	31.21	22.10	—
Chemicals	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Material Cost (%)	41.20	40.97	48.30	43.67	35.43	42.98	40.89	39.01	38.32	6.03
Employee Cost	37.84	40.95	41.88	46.61	50.37	53.98	57.67	65.18	61.80	63.81
Power & Fuel Cost	2.26	2.12	1.00	1.41	0.76	0.52	0.47	0.29	0.17	—
Operating Profit	11.81	5.77	-11.11	9.34	8.53	19.08	25.03	34.15	23.07	51.07
Other Income	0.66	0.47	0.46	1.43	2.53	4.39	3.43	5.73	9.28	8.19
OPM (%)	8.23	4.01	-8.78	5.60	5.38	10.15	11.50	14.43	11.05	19.01
Depreciation and Amortisation	3.09	1.99	0.32	1.02	1.13	1.09	1.53	1.21	1.66	8.13
Interest	5.30	2.64	0.66	0.75	0.51	0.51	0.28	0.41	0.81	0.96
Profit Before Tax	4.08	14.40	-11.63	9.00	9.41	21.87	26.64	34.81	29.87	69.86
Tax	0.82	2.53	-0.08	1.79	1.54	4.81	7.79	8.09	7.41	14.50
Net Profit	3.25	11.86	-11.55	7.22	7.87	17.06	18.86	26.72	22.46	55.36
Number of shares(Crs)	2.62	2.62	2.62	2.62	2.62	2.62	2.62	2.62	2.64	—
Dividend Payout Ratio(%)	8.05	2.21	—	9.08	16.64	15.36	55.58	49.02	58.85	—

TTM Values as of Mar 2025

Cash Flow

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash from Operating Activity	9.04	-3.24	-1.58	30.90	11.89	28.22	6.91	46.66	35.17	55.30
Profit Before Tax	4.08	14.40	-11.63	9.00	9.41	21.87	26.64	34.81	29.87	69.86
Adjustments	7.73	-8.63	1.26	0.33	-0.57	-2.09	-1.40	9.63	8.27	-11.56
OCF Before Working Capital	11.81	5.77	-10.36	9.34	8.85	19.78	25.24	44.44	38.14	58.30
Working Capital Changes	-1.96	-6.13	8.79	19.71	4.84	11.59	-11.46	9.50	5.54	5.14
Taxes Paid	-0.82	-2.88	—	1.85	-1.80	-3.15	-6.87	-7.28	-8.51	-8.14
Cash from Investing Activity	-2.09	41.29	-3.37	-0.83	-11.07	-2.26	-25.78	-57.67	-24.55	-45.15
Net Fixed Assets Purchased	-2.75	40.82	-3.83	-2.25	-1.67	-0.47	-0.47	0.98	-0.25	35.37
Fixed Assets Purchased	-2.75	-2.58	-3.83	-2.25	-1.85	-0.47	-1.05	-0.32	-0.25	-0.35
Fixed Assets Sold	—	43.40	—	—	0.18	—	0.58	1.30	—	35.72
Investment Purchased	—	—	—	—	-11.39	-4.17	-26.86	-106	-135	—
Investment Sold	—	—	—	—	—	—	—	43.82	104	—
Interest Recieved	—	—	—	—	2.17	2.38	1.55	3.43	7.37	7.84
Dividends Recieved	0.00	—	—	—	—	—	—	—	—	—
Subsidiary Investments	—	—	—	—	—	—	—	—	—	—
Cash from Financing Activity	-6.43	-33.52	-0.60	-6.05	-1.82	-6.83	-17.55	-0.46	-8.91	-11.70
Proceeds From Shares	—	—	—	—	—	-3.69	-15.39	—	5.63	—
Net Long Term Borrowings	0.00	0.00	0.00	0.00	0.00	0.00	-6.79	0.00	0.00	0.00
Proceeds From Borrowings	—	—	—	—	—	—	—	—	—	—
Repayment From Borrowings	—	—	—	—	—	—	-6.79	—	—	—
Interest Paid	-5.30	-2.64	-0.66	-0.75	-0.51	-0.51	-0.28	-0.41	-0.81	-0.10
Dividend Paid	-0.26	-0.26	-0.26	-0.66	-1.31	-2.62	-10.48	—	-13.10	-13.23
Net Cash Flow	0.52	4.53	-5.55	24.02	-1.01	19.13	-36.42	-11.47	1.71	-1.54
Opening Cash & Cash Equivalents	15.02	15.53	20.06	14.51	40.82	39.81	58.94	22.53	11.05	12.76
Effect of FX	—	—	—	—	—	—	—	—	—	—
Closing Cash & Cash Equivalents	15.53	20.06	14.51	38.53	39.81	58.94	22.53	11.05	12.76	11.21
Net Capex (est)	2.75	-40.82	3.83	2.25	1.67	0.47	0.47	-0.98	0.25	-35.37
Free Cash Flow (est)	6.29	37.58	-5.40	28.64	10.21	27.75	6.45	47.63	34.92	90.67

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	1.14	1.07	2.12	1.51	2.30	1.94	2.25	2.53	4.31	6.35
Liquid Assets (Crs)	62.73	61.12	62.50	43.18	64.87	66.98	90.75	86.51	151	176
Current Liabilities (Crs)	55.19	57.31	29.44	28.58	28.19	34.57	40.40	34.14	35.18	27.64
Current Ratio	1.74	1.76	3.74	3.31	3.46	2.79	2.98	3.40	4.89	6.90
Current Assets (Crs)	95.79	101	110	94.61	97.56	96.31	120	116	172	191
Current Liabilities (Crs)	55.19	57.31	29.44	28.58	28.19	34.57	40.40	34.14	35.18	27.64
Interest Coverage Ratio	1.37	1.77	6.44	-16.69	13.08	19.31	43.59	94.48	85.28	37.69
EBIT (Crs)	6.13	9.37	4.24	-10.97	9.75	9.93	22.39	26.93	38.68	30.68
Interest Expenses (Crs)	4.46	5.30	2.64	0.66	0.75	0.51	0.51	0.28	0.41	0.81
Fixed Asset Turnover	1.58	1.59	2.72	2.36	3.03	2.73	3.13	3.74	7.20	18.01
Net Sales (Crs)	138	143	144	127	167	159	188	218	237	209
Fixed Assets (Crs)	87.61	90.35	52.88	53.66	55.00	58.17	60.12	58.13	32.87	11.59
Cash Conversion Cycle	176	159	163	182	89.75	43.39	23.23	-9.07	-7.78	-0.27
Inventory Days	83.52	92.27	110	143	92.03	71.38	57.34	44.76	35.78	29.02
Days Receivable	118	110	102	93.07	50.22	48.57	33.13	21.26	25.87	25.88
Days Payable	26.19	43.17	49.18	53.98	52.49	76.56	67.24	75.08	69.43	55.17
Debt to Equity Ratio	0.41	0.39	0.07	0.08	0.04	0.06	0.06	0.00	0.00	0.00
Total Debt (Crs)	39.31	38.49	7.93	8.30	3.79	6.40	6.79	0.00	0.00	0.00
Shareholders Equity (Crs)	95.43	98.36	110	98.05	104	111	122	133	159	187
Free Cash Flow/Sales (%)	2.69	4.38	26.12	-4.27	17.17	6.44	14.77	2.96	20.12	16.73
Free Cash Flow(est) (Crs)	3.72	6.29	37.58	-5.40	28.64	10.21	27.75	6.45	47.63	34.92
Net Sales (Crs)	138	143	144	127	167	159	188	218	237	209
Profitability Ratios
Gross Margin (%)	50.28	58.80	59.03	51.70	56.33	64.57	57.02	59.11	60.99	61.68
Op Profit Margin (%)	6.32	8.23	4.01	-8.78	5.60	5.38	10.15	11.50	14.43	11.05
Operating Profit (Crs)	8.84	12.47	6.24	-10.65	10.76	11.06	23.47	28.45	39.89	32.35
Net Sales (Crs)	138	143	144	127	167	159	188	218	237	209
Net Profit Margin (%)	0.85	2.27	8.25	-9.13	4.33	4.96	9.08	8.67	11.29	10.76
Net Profit (Crs)	1.17	3.25	11.86	-11.55	7.22	7.87	17.06	18.86	26.72	22.46
Net Sales (Crs)	138	143	144	127	167	159	188	218	237	209
ROCE (%)	6.19	9.19	3.75	-10.84	9.06	8.70	18.08	19.62	23.11	15.50
EBIT (Crs)	6.13	9.37	4.24	-10.97	9.75	9.93	22.39	26.93	38.68	30.68
Capital Employed (Crs)	99.03	102	113	101	108	114	124	137	167	198
Return on Assets (%)	0.76	2.04	8.32	-8.90	5.31	5.29	10.39	11.00	13.19	9.96
Net Profit (Crs)	1.17	3.25	11.86	-11.55	7.22	7.87	17.06	18.86	26.72	22.46
Total Assets (Crs)	154	159	143	130	136	149	164	171	203	226
ROIC (%)	5.44	8.73	3.78	-14.96	11.82	12.97	32.93	27.59	49.65	51.72
Op Profit after Taxes (Crs)	4.22	6.96	3.11	-11.35	6.67	6.19	14.03	16.63	25.29	16.10
Invested Capital (Crs)	77.55	79.73	82.21	75.88	56.43	47.72	42.61	60.27	50.93	31.12
ROE (%)	1.23	3.31	10.79	-11.78	6.91	7.09	13.99	14.20	16.82	11.99
Net Profit Margin (%)	0.85	2.27	8.25	-9.13	4.33	4.96	9.08	8.67	11.29	10.76
Asset Turnover ratio	0.90	0.90	1.01	0.97	1.23	1.07	1.14	1.27	1.17	0.93
Equity Multiplier	1.62	1.62	1.30	1.32	1.30	1.34	1.35	1.29	1.27	1.20
Adjusted EPS	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40
Valuation Ratios
P/E	63.76	26.37	8.41	0.00	9.55	5.81	12.22	43.57	28.42	32.94
Price to Book	0.85	0.95	0.98	0.78	0.71	0.44	1.83	6.19	5.06	4.34
EV/EBITDA	11.20	8.72	14.06	-6.03	3.17	1.05	6.60	27.99	16.17	18.30
Dividend Yield (%)	0.35	0.31	0.26	0.37	0.95	2.87	1.26	1.28	1.72	1.79

Quarterly Results

Jagsonpal Pharmaceuticals Ltd.
Bliss GVS Pharma
Loading...
Beta Drugs
Loading...

In Rs. Cr.	Dec'22	Mar'23	Jun'23	Sep'23	Dec'23	Mar'24	Jun'24	Sep'24	Dec'24	Mar'25
Net Sales	60.14	55.45	60.15	57.83	47.23	43.49	61.44	74.69	74.03	58.56
Operating Expenses	51.51	50.01	51.52	49.46	43.84	40.82	51.20	58.41	58.19	49.85
Increase/Decrease in Stock	1.25	-1.61	1.17	1.20	-0.29	1.81	-2.12	-0.87	0.13	0.74
Raw Material	6.12	6.32	7.53	4.91	5.88	3.79	4.39	5.20	5.27	3.48
Employee Cost	14.20	13.21	13.70	11.70	11.64	11.64	14.74	16.68	16.82	15.58
Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gen_AdminExpenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Miscellaneous Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Profit	8.63	5.44	8.64	8.37	3.40	2.67	10.24	16.29	15.83	8.71
Other Income	1.74	2.56	2.00	2.27	2.52	2.49	1.44	1.65	2.32	2.77
Interest	0.18	0.20	0.15	0.22	0.23	0.22	0.21	0.23	0.26	0.26
PBDT	10.20	7.80	10.48	10.42	5.69	4.94	8.18	17.71	41.09	11.01
Depreciation and Amortization	0.33	0.48	0.39	0.46	0.41	0.40	1.07	2.34	2.41	2.31
Profit Before Tax	9.87	7.32	10.09	9.96	5.28	4.54	7.11	15.37	38.67	8.71
Tax	2.08	1.72	2.61	2.49	1.32	0.99	1.78	3.91	6.68	2.13
Profit After Tax	7.79	5.60	7.48	7.47	3.96	3.55	5.33	11.46	31.99	6.58
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	-3.29	0.00	23.18	-0.21
Net Profit	7.79	5.60	7.48	7.47	3.96	3.55	5.33	11.46	31.99	6.58
Quarterly Ratios
EPS	1.19	0.86	1.14	1.14	0.60	0.54	0.81	1.73	1.93	0.99
Operating Profit Margin	14.36	9.81	14.36	14.47	7.19	6.14	16.66	21.80	21.39	14.88
Net Profit Margin	12.94	10.10	12.43	12.92	8.39	8.16	8.67	15.34	43.22	11.24

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

36.50%

Implied Growth Rate over a 5 year period*

12.50%

Implied Growth Rate over a 10 year period*

5.10%

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Raphson method.

Learn how to use Reverse DCF

FAQs on Jagsonpal Pharmaceuticals Ltd. Financials

How strong is Jagsonpal Pharma balance sheet?

Balance sheet of Jagsonpal Pharma is strong.
It shouldn't have solvency or liquidity issues.

Is the debt of Jagsonpal Pharma increasing or decreasing?

Yes, The net debt of Jagsonpal Pharma is increasing.
Latest net debt of Jagsonpal Pharma is -₹128.73 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹295.87 Crs.

Is the profitablity of Jagsonpal Pharma improving?

The profit is oscillating.
The profit of Jagsonpal Pharma is ₹55.36 Crs for TTM, ₹22.46 Crs for Mar 2024 and ₹26.72 Crs for Mar 2023.

Does Jagsonpal Pharma pay decent dividends?

The company seems to pay a good stable dividend.
Jagsonpal Pharma latest dividend payout ratio is 58.85% and 3yr average dividend payout ratio is 54.48%

How has Jagsonpal Pharma allocated its funds?

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd.

Has the share price of Jagsonpal Pharma grown faster than its competition?

Is Jagsonpal Pharma stock expensive?

How strong is Jagsonpal Pharma balance sheet?

Is the debt of Jagsonpal Pharma increasing or decreasing?

Is the profitablity of Jagsonpal Pharma improving?

Does Jagsonpal Pharma pay decent dividends?

How has Jagsonpal Pharma allocated its funds?

SIGN UP FOR FREE